Published in Gene Therapy Weekly, September 14th, 2006
"The majority of inhibitory neurotransmission in the brain is mediated by the GABA(A) receptor. The anticonvulsant loreclezole largely acts by potentiating GABA(A) receptors containing beta 2 and beta 3 subunits.
"We used a genetically modified mouse containing a loreclezole-insensitive beta 2 subunit (beta 2N265S) to determine the role of this subunit in mediating the sedative and anticonvulsive effects of loreclezole," wrote J.O. Groves and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.